Literature DB >> 26979861

Hepatitis B virus receptors and molecular drug targets.

Eloi R Verrier1,2, Che C Colpitts1,2, Camille Sureau3, Thomas F Baumert4,5,6.   

Abstract

Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Virus-induced diseases include cirrhosis, liver failure and hepatocellular carcinoma. Current therapeutic strategies may at best control infection without reaching cure. Complementary antiviral strategies aimed at viral cure are therefore urgently needed. HBV entry is the first step of the infection cycle, which leads to the formation of cccDNA and the establishment of chronic infection. Viral entry may thus represent an attractive target for antiviral therapy. This review summarizes the molecular virology and cell biology of HBV entry, including the discovery and development of new HBV entry inhibitors, and discusses their potential in future treatment of HBV infection.

Entities:  

Keywords:  Antiviral targets; Host-targeting agents; Liver; Therapy; Treatment

Mesh：

Substances：

Year:  2016        PMID： 26979861      PMCID： PMC7613476          DOI： 10.1007/s12072-016-9718-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   9.029


  67 in total

Review 1.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.

Authors:  Manabu Kaneko; Koichi Watashi; Shinji Kamisuki; Hiroki Matsunaga; Masashi Iwamoto; Fumihiro Kawai; Hirofumi Ohashi; Senko Tsukuda; Satomi Shimura; Ryosuke Suzuki; Hideki Aizaki; Masaya Sugiyama; Sam-Yong Park; Takayoshi Ito; Naoko Ohtani; Fumio Sugawara; Yasuhito Tanaka; Masashi Mizokami; Camille Sureau; Takaji Wakita
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

3.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

Authors:  M A Sells; M L Chen; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

4.  Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Authors:  Heiner Wedemeyer; Cihan Yurdaydìn; George N Dalekos; Andreas Erhardt; Yilmaz Çakaloğlu; Halil Değertekin; Selim Gürel; Stefan Zeuzem; Kalliopi Zachou; Hakan Bozkaya; Armin Koch; Thomas Bock; Hans Peter Dienes; Michael P Manns
Journal:  N Engl J Med       Date:  2011-01-27       Impact factor: 91.245

5.  Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.

Authors:  Matthieu Blanchet; Camille Sureau; Patrick Labonté
Journal:  Antiviral Res       Date:  2014-04-06       Impact factor: 5.970

6.  Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties.

Authors:  Eithan Galun; Rachel Eren; Rifaat Safadi; Yaffa Ashour; Norah Terrault; Emmet B Keeffe; Edith Matot; Sara Mizrachi; Dov Terkieltaub; Merav Zohar; Ido Lubin; Judith Gopher; Daniel Shouval; Shlomo Dagan
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

7.  Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.

Authors:  Shirin Nkongolo; Yi Ni; Florian A Lempp; Christina Kaufman; Thomas Lindner; Katharina Esser-Nobis; Volker Lohmann; Walter Mier; Stefan Mehrle; Stephan Urban
Journal:  J Hepatol       Date:  2013-12-01       Impact factor: 25.083

8.  Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.

Authors:  B Hagenbuch; P J Meier
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Liver transplantation in European patients with the hepatitis B surface antigen.

Authors:  D Samuel; R Muller; G Alexander; L Fassati; B Ducot; J P Benhamou; H Bismuth
Journal:  N Engl J Med       Date:  1993-12-16       Impact factor: 91.245

Review 10.  Glypicans.

Authors:  Jorge Filmus; Mariana Capurro; Jonathan Rast
Journal:  Genome Biol       Date:  2008-05-22       Impact factor: 13.583
View more
  8 in total

Review 1.  Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Authors:  Sebastien Boucle; Leda Bassit; Maryam Ehteshami; Raymond F Schinazi
Journal:  Clin Liver Dis       Date:  2016-08-30       Impact factor: 6.126

2.  Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.

Authors:  Inna Tulaeva; Carolin Cornelius; Petra Zieglmayer; René Zieglmayer; René Schmutz; Patrick Lemell; Milena Weber; Margarete Focke-Tejkl; Alexander Karaulov; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2020-08-24       Impact factor: 8.143

3.  Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes.

Authors:  Eloi R Verrier; Seung-Ae Yim; Laura Heydmann; Houssein El Saghire; Charlotte Bach; Vincent Turon-Lagot; Laurent Mailly; Sarah C Durand; Julie Lucifora; David Durantel; Patrick Pessaux; Nicolas Manel; Ivan Hirsch; Mirjam B Zeisel; Nathalie Pochet; Catherine Schuster; Thomas F Baumert
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.298

Review 4.  Membranotropic peptides mediating viral entry.

Authors:  Annarita Falanga; Massimiliano Galdiero; Giancarlo Morelli; Stefania Galdiero
Journal:  Pept Sci (Hoboken)       Date:  2018-02-13

5.  Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Authors:  Eloi R Verrier; Amélie Weiss; Charlotte Bach; Laura Heydmann; Vincent Turon-Lagot; Arnaud Kopp; Houssein El Saghire; Emilie Crouchet; Patrick Pessaux; Thomas Garcia; Patrick Pale; Mirjam B Zeisel; Camille Sureau; Catherine Schuster; Laurent Brino; Thomas F Baumert
Journal:  Gut       Date:  2019-03-04       Impact factor: 31.793

Review 6.  Novel therapeutic targets for cholestatic and fatty liver disease.

Authors:  Michael Trauner; Claudia Daniela Fuchs
Journal:  Gut       Date:  2021-10-06       Impact factor: 23.059

Review 7.  Targeting the Host for New Therapeutic Perspectives in Hepatitis D.

Authors:  Vincent Turon-Lagot; Antonio Saviano; Catherine Schuster; Thomas F Baumert; Eloi R Verrier
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

Review 8.  Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection.

Authors:  Eloi R Verrier; Che C Colpitts; Catherine Schuster; Mirjam B Zeisel; Thomas F Baumert
Journal:  Viruses       Date:  2016-09-20       Impact factor: 5.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.